home · filing · 0001193125-26-228133
8-K filed May 18, 2026, 9:33 AM ET
ticker QNCX
CIK 0001662774
M&A
confidence high
sentiment neutral
materiality 1.00
Quince Therapeutics, Inc. (QNCX): M&A transaction — Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts
Quince Therapeutics, Inc.
Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.
Pre-transaction Quince holders will own ~6.9% post-financing; new Investors hold ~61.2%.
PIPE of $115M via sale of Series C Preferred and warrants; warrants could add ~$72M.
Dr. Brigette Roberts appointed to Board and as Chief of Corporate Affairs; salary $600K.
Retention bonuses of $700K for CEO Dirk Thye and $500K for COO Brendan Hannah, contingent on stockholder approval.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2026-05-18
Filed May 18, 2026, 9:33 AM ET
Brigette Roberts, M.D., was appointed to the Board as a Class III director.
Effective 2026-05-18
Filed May 18, 2026, 9:33 AM ET
Dr. Roberts was also appointed as the Chief of Corporate Affairs of the Company.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brigette Roberts was appointed as Director at Quince Therapeutics, Inc..
Action appointed
Role Director
Exact text from the filing
Brigette Roberts, M.D., was appointed to the Board as a Class III director.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brigette Roberts was appointed as Chief of Corporate Affairs at Quince Therapeutics, Inc..
Action appointed
Role Chief of Corporate Affairs
Exact text from the filing
Dr. Roberts was also appointed as the Chief of Corporate Affairs of the Company.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Quince Therapeutics, Inc.: Filed Certificate of Designation creating Series C Preferred Stock (effective 2026-05-18).
Change charter amendment
Effective 2026-05-18
Exact text from the filing
On May 18, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the " Certificate of Designation ") in connection with the Acquisition and the Financing referenced in Item 1.01 above.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Quince Therapeutics, Inc. completed an acquisition involving Orphai Therapeutics, LLC and Orphai Holdings Therapeutics, Inc. (closed 2026-05-18).
Action acquisition
Counterparty Orphai Therapeutics, LLC and Orphai Holdings Therapeutics, Inc.
Closing 2026-05-18
Exact text from the filing
On May 18, 2026, the Company completed its acquisition of the Orphai Entities.
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-26-228133
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.